Thomas Gasser

发表

Controls-based denoising, a new approach for medical image analysis, improves prediction of conversion to Alzheimer’s disease with FDG-PET

Matthias Reimold, Dominik Blum, Inga Liepelt-Scarfone, 2019, European Journal of Nuclear Medicine and Molecular Imaging.

Ein neuartiges passives Paradigma der funktionellen Magnetresonanztomographie (fMRT) zur Hirnfunktionsanalyse (A Novel Passive Paradigm for Functional Magnetic Resonance Imaging (fMRI) to Localize Brain Functions)

Volker Skwarek, Thomas Gasser, Volker Hans, 2003 .

Intraoperative functional MRI: Implementation and preliminary experience

Christopher Nimsky, Oliver Ganslandt, Rudolf Fahlbusch, 2005, NeuroImage.

Virtual Machine and Code Generator for PLC-Systems

Thomas Gasser, 2013 .

[11C]PIB binding in Parkinson's disease dementia

Matthias Reimold, Walter Maetzler, Daniela Berg, 2008, NeuroImage.

Reduction of susceptibility-induced signal losses in multi-gradient-echo images: Application to improved visualization of the subthalamic nucleus

Ralf Deichmann, Christine Preibisch, Steffen Volz, 2009, NeuroImage.

Role of sepiapterin reductase gene at the PARK3 locus in Parkinson's disease

Aldo Quattrone, Nobutaka Hattori, Anthony E. Lang, 2011, Neurobiology of Aging.

IdentIFICatIon oF noVel BIoMarKer CandIdates In tHe CereBrosPInal FluId ProteoMe oF druG-naïVe ParKInson’s dIsease PatIents

Thomas Gasser, Thang V. Pham, Henk W. Berendse, 2014 .

Movement disorder society criteria for clinically established early Parkinson's disease

Günther Deuschl, Bastiaan R Bloem, Inga Liepelt-Scarfone, 2018, Movement disorders : official journal of the Movement Disorder Society.

Enlarged hyperechogenic substantia nigra as a risk marker for Parkinson's disease

Klaus Fassbender, Stefanie Behnke, Inga Liepelt-Scarfone, 2013, Movement disorders : official journal of the Movement Disorder Society.

Complex relationship between Parkin mutations and Parkinson disease.

Jean-François Deleuze, Vincenzo Bonifati, Thomas Gasser, 2002, American journal of medical genetics.

The PARK8 locus in autosomal dominant parkinsonism: confirmation of linkage and further delineation of the disease-containing interval.

Bertram Müller-Myhsok, Manu Sharma, Thomas Gasser, 2004, American journal of human genetics.

Genome-wide Pleiotropy Between Parkinson Disease and Autoimmune Diseases

Nicholas W Wood, Andre Franke, Manu Sharma, 2017, JAMA neurology.

How much phenotypic variation can be attributed to parkin genotype?

Alexandra Durr, Valérie Fraix, Vincenzo Bonifati, 2003, Annals of neurology.

Enlarged substantia nigra hyperechogenicity and risk for Parkinson disease: a 37-month 3-center study of 1847 older persons.

Jochen Klenk, Klaus Fassbender, Stefanie Behnke, 2011, Archives of neurology.

Loss-of-function mutations in RAB39B are associated with typical early-onset Parkinson disease

Nicholas W. Wood, Thomas Gasser, John Hardy, 2015, Neurology: Genetics.

Novel mutation in the TOR1A (DYT1) gene in atypical, early onset dystonia and polymorphisms in dystonia and early onset parkinsonism

Christine Klein, Peter P. Pramstaller, Thomas Gasser, 2001, Neurogenetics.

Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies

Mohamad Saad, Nicholas W Wood, Manu Sharma, 2011, The Lancet.

Dual-Task Performance in GBA Parkinson's Disease

Michael Schwenk, Walter Maetzler, Daniela Berg, 2017, Parkinson's disease.

Mutations in the pantothenate kinase gene PANK2 are not associated with Parkinson disease

Bertram Müller-Myhsok, Thomas Gasser, Thomas Klopstock, 2005, Neuroscience Letters.

NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases

Nicholas Eriksson, Margaret Sutherland, Mohamad Saad, 2015, Neurobiology of Aging.

Derivation and Expansion Using Only Small Molecules of Human Neural Progenitors for Neurodegenerative Disease Modeling

Thomas Gasser, Cora S. Thiel, Peter Reinhardt, 2013, PloS one.

Parkinson’s Disease and Dementia: A Longitudinal Study (DEMPARK)

Günther Deuschl, Carola Seifried, Oliver Riedel, 2011, Neuroepidemiology.

Update of the MDS research criteria for prodromal Parkinson's disease

Sebastian Heinzel, Daniela Berg, Thomas Gasser, 2019, Movement disorders : official journal of the Movement Disorder Society.

Personalized Medicine Approaches in Parkinson's Disease: The Genetic Perspective.

Thomas Gasser, T. Gasser, 2016, Journal of Parkinson's disease.

Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson′s disease

Thomas Gasser, Erwin Ott, F. Asmus, 2003, Neurogenetics.

The specificity and sensitivity of transcranial ultrasound in the differential diagnosis of Parkinson's disease: a prospective blinded study

Matthias Reimold, Daniela Berg, Thomas Gasser, 2008, The Lancet Neurology.

Discovery and functional prioritization of Parkinson’s disease candidate genes from large-scale whole exome sequencing

Jean-François Dartigues, Günther Deuschl, Yoav Ben-Shlomo, 2017, Genome Biology.

The natural history of multiple system atrophy: a prospective European cohort study

Günther Deuschl, Nir Giladi, Niall P Quinn, 2013, The Lancet Neurology.

PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation.

Vesna Sossi, Thomas Gasser, John R. Adams, 2005, Brain : a journal of neurology.

Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria

Thomas Gasser, James B Leverenz, John Hardy, 2009, The Lancet Neurology.

Genes associated with Parkinson syndrome

Saskia Biskup, Thomas Gasser, Andreas Kupsch, 2008, Journal of Neurology.

Priorities in Parkinson's disease research

Paola Piccini, Thomas Gasser, Erwan Bezard, 2011, Nature Reviews Drug Discovery.

Minocycline 1‐year therapy in multiple‐system‐atrophy: Effect on clinical symptoms and [11C] (R)‐PK11195 PET (MEMSA‐trial)

Alexander Gerhard, Günther Deuschl, Federico Turkheimer, 2010, Movement disorders : official journal of the Movement Disorder Society.

Polymorphisms in the glial glutamate transporter SLC1A2 are associated with essential tremor

Günther Deuschl, Thomas Gasser, Kaare Christensen, 2012, Neurology.

Diagnosis of Parkinson's disease on the basis of clinical and genetic classification: a population-based modelling study

Margaret Sutherland, John P A Ioannidis, Daniel Weintraub, 2015, The Lancet Neurology.

Pilot whole-exome sequencing of a German early-onset Alzheimer's disease cohort reveals a substantial frequency of PSEN2 variants

Florian G. Metzger, Patrizia Rizzu, Walter Maetzler, 2016, Neurobiology of Aging.

Genetic comorbidities in Parkinson's disease.

Mohamad Saad, Anette Schrag, Thomas Gasser, 2014, Human molecular genetics.

Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis

Edwin Cuppen, Christine Klein, Dagmar Verbaan, 2011, Annals of neurology.

Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk.

Peter Holmans, Alexandra Durr, Manu Sharma, 2013, JAMA neurology.

Genome-Scale Networks Link Neurodegenerative Disease Genes to α-Synuclein through Specific Molecular Pathways.

Bonnie Berger, Ernest Fraenkel, Marc Vidal, 2017, Cell systems.

Deep-brain-stimulation does not impair deglutition in Parkinson's disease.

Christian Plewnia, Thomas Gasser, Daniel Weiss, 2012, Parkinsonism & related disorders.

The new definition and diagnostic criteria of Parkinson's disease

Günther Deuschl, Bastiaan R Bloem, Inga Liepelt-Scarfone, 2016, The Lancet Neurology.

Red flags for multiple system atrophy

Günther Deuschl, Nir Giladi, Carlo Colosimo, 2008, Movement disorders : official journal of the Movement Disorder Society.

Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology

Thomas Meitinger, Bertram Müller-Myhsok, Saskia Biskup, 2004, Neuron.

Use of support vector machines for disease risk prediction in genome‐wide association studies: Concerns and opportunities

Andreas Zell, Andreas Jahn, Mohamad Saad, 2012, Human mutation.

The LRRK2 I2012T, G2019S, and I2020T mutations are rare in Taiwanese patients with sporadic Parkinson's disease.

Nobutaka Hattori, Yi-Hsin Weng, Vincenzo Bonifati, 2005, Parkinsonism & related disorders.

Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease.

Mohamad Saad, Peter Holmans, Nicholas W Wood, 2013, Human molecular genetics.

MDS research criteria for prodromal Parkinson's disease

Günther Deuschl, Lawrence Joseph, Daniela Berg, 2015, Movement disorders : official journal of the Movement Disorder Society.

Genetic correction of a LRRK2 mutation in human iPSCs links parkinsonian neurodegeneration to ERK-dependent changes in gene expression.

Torsten Kluba, Daniela Berg, Thomas Gasser, 2013, Cell stem cell.

Genetics of Parkinson's disease

Thomas Gasser, T. Gasser, 2005, Current opinion in neurology.

The Ile93Met mutation in the ubiquitin carboxy-terminal-hydrolase-L1 gene is not observed in European cases with familial Parkinson's disease

Nicholas W. Wood, Matthew J. Farrer, Vincenzo Bonifati, 1999, Neuroscience Letters.

A missense mutation in KCTD17 causes autosomal dominant myoclonus-dystonia.

Deborah Hughes, Christine Klein, Thomas Foltynie, 2015, American journal of human genetics.

The differential diagnosis and treatment of tremor.

Volker Tronnier, Thomas Gasser, Kai Bötzel, 2014, Deutsches Arzteblatt international.